Regulus Therapeutics Inc. (NASDAQ:RGLS) Receives Consensus Rating of "Hold" from Analysts

Shares of Regulus Therapeutics Inc. (NASDAQ:RGLS - Get Free Report) have earned a consensus recommendation of "Hold" from the seven ratings firms that are covering the stock, MarketBeat reports. Five research analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $8.50.

RGLS has been the topic of a number of recent analyst reports. Leerink Partnrs lowered shares of Regulus Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, April 30th. Canaccord Genuity Group reissued a "hold" rating and issued a $11.00 price objective (down from $28.00) on shares of Regulus Therapeutics in a research report on Wednesday, April 30th. Jones Trading reissued a "hold" rating and issued a $7.00 price objective (down from $8.00) on shares of Regulus Therapeutics in a research report on Wednesday, April 30th. Wall Street Zen assumed coverage on shares of Regulus Therapeutics in a research report on Sunday, May 18th. They issued a "sell" rating on the stock. Finally, Leerink Partners reaffirmed a "market perform" rating and set a $7.00 target price on shares of Regulus Therapeutics in a research report on Wednesday, April 30th.

Hedge Funds Weigh In On Regulus Therapeutics

Institutional investors have recently modified their holdings of the stock. Federated Hermes Inc. boosted its stake in shares of Regulus Therapeutics by 23.1% during the first quarter. Federated Hermes Inc. now owns 15,819,863 shares of the biopharmaceutical company's stock valued at $27,685,000 after purchasing an additional 2,967,209 shares in the last quarter. Octagon Capital Advisors LP boosted its stake in shares of Regulus Therapeutics by 13.7% during the fourth quarter. Octagon Capital Advisors LP now owns 4,848,802 shares of the biopharmaceutical company's stock valued at $7,661,000 after purchasing an additional 585,101 shares in the last quarter. Baker BROS. Advisors LP bought a new position in shares of Regulus Therapeutics during the first quarter valued at approximately $4,715,000. Millennium Management LLC boosted its stake in shares of Regulus Therapeutics by 69.7% during the fourth quarter. Millennium Management LLC now owns 2,192,158 shares of the biopharmaceutical company's stock valued at $3,464,000 after purchasing an additional 900,743 shares in the last quarter. Finally, Driehaus Capital Management LLC bought a new position in shares of Regulus Therapeutics during the first quarter valued at approximately $1,677,000. 92.38% of the stock is owned by hedge funds and other institutional investors.

Regulus Therapeutics Price Performance

Shares of Regulus Therapeutics stock traded up $0.01 during trading hours on Friday, reaching $7.94. The company's stock had a trading volume of 819,067 shares, compared to its average volume of 905,897. The firm has a 50 day moving average price of $4.45 and a 200-day moving average price of $2.45. Regulus Therapeutics has a one year low of $0.83 and a one year high of $8.20. The stock has a market cap of $549.72 million, a P/E ratio of -7.42 and a beta of 0.49.

Regulus Therapeutics (NASDAQ:RGLS - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, topping analysts' consensus estimates of ($0.29) by $0.14. As a group, sell-side analysts forecast that Regulus Therapeutics will post -0.88 EPS for the current fiscal year.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.